12 PENNS TRAIL, NEWTOWN, PA
Provides Updated Guidance on Influenza Prophylaxis Program
Provides Regulatory Update on Influenza Program
Annual Report to Security Holders
Traws Pharma Enters $50 Million At The Market Offering Agreement
Provides Business Highlights and Reports Q1 2026 Financial Results
Reports Full Year 2025 Results and Provides Business Highlights
Announces Up to $60 Million Private Placement Financing
Traws Pharma Updates on Ratutrelvir Study and Tivoxavir for Influenza
Q1
FY 2025
Notice of Late Filing for Annual Report
Q3
Q2
Amended Annual Report
FY 2024
Registration Statement for Securities Offered under a Shelf Registration
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Prospectus filed pursuant to Rule 424(b)(3)
Definitive Proxy Statement
Additional Proxy Materials
PRE 14A
Amended Schedule 13G - Ownership Report
Amended Schedule 13D - Ownership Report
Statement of Changes in Beneficial Ownership
Initial Statement of Beneficial Ownership